Customized co-encapsulation services for multi-payload lipid nanoparticles, including RNA-RNA, RNA-protein, RNA-peptide, RNA-small molecule, protein-adjuvant-like component, and hydrophilic-hydrophobic payload combinations.
Co-encapsulation of multiple payloads in lipid nanoparticles is increasingly used in combination delivery research, gene regulation studies, protein expression modulation, immune-cell interaction models, and multi-mechanism drug delivery exploration. Compared with single-payload LNP formulation, multi-payload LNP development is more complex because each cargo may differ in molecular size, charge density, hydrophilicity, structural sensitivity, solvent compatibility, and release behavior. A formulation that efficiently encapsulates one payload may reduce the loading, stability, or functional signal of another. BOC Sciences provides co-encapsulation of multiple payloads in LNPs services to help pharmaceutical and biotechnology researchers design, prepare, purify, and characterize multi-cargo LNP systems with controlled particle attributes, balanced payload ratios, reduced free payload interference, and interpretable performance data for in vitro evaluation and formulation comparison.
Multi-payload LNP systems require a formulation strategy that considers not only each individual cargo, but also cargo-cargo interaction, lipid-cargo association, mixing sequence, purification compatibility, and payload ratio preservation. BOC Sciences supports customized co-encapsulation projects from feasibility screening to optimized LNP preparation, helping research teams evaluate whether different payloads can be incorporated into a single lipid nanoparticle platform without compromising particle quality or downstream biological interpretation.
Co-encapsulation of multiple nucleic acid payloads is suitable for studies requiring coordinated gene expression, gene silencing, pathway modulation, or multiplexed RNA delivery in the same cellular model. BOC Sciences supports LNP encapsulation for combinations such as mRNA-siRNA, mRNA-miRNA, siRNA-siRNA, gRNA-donor template, and other nucleic acid systems with different molecular lengths, charge densities, and structural behaviors.
Nucleic acid-small molecule co-encapsulation is used when researchers need to combine RNA-based modulation with pathway intervention, intracellular signaling adjustment, imaging-related molecules, or functional chemical tools. These systems require careful control because nucleic acids are commonly retained through ionizable lipid association, while small molecules may partition into the lipid matrix, aqueous phase, or particle interface depending on their solubility and ionization state.
Co-encapsulation of nucleic acids with proteins or peptides is valuable for research involving RNA-protein cooperation, intracellular functional modulation, antigen-related studies, enzyme delivery exploration, peptide-assisted delivery, or RNP-like assemblies. Compared with nucleic acid-only LNPs, these formulations must address protein conformation, peptide charge, aggregation risk, nucleic acid stability, and potential cargo-cargo interaction during LNP self-assembly.
Triple-payload and higher-order LNP co-encapsulation is designed for complex research models where three or more functional components need to be delivered together, such as multi-RNA combinations, RNA-protein-small molecule systems, RNA-peptide-adjuvant-like component systems, or multi-mechanism formulation studies. These projects require systematic formulation screening because each additional payload may affect particle formation, payload ratio preservation, purification recovery, and downstream assay interpretation.
Multi-payload LNP formulation can follow different co-encapsulation routes depending on cargo compatibility, molecular size, charge behavior, solubility, intended intracellular function, and desired release pattern. BOC Sciences supports several co-encapsulation types, helping researchers select a practical strategy for nucleic acid-nucleic acid, nucleic acid-small molecule, nucleic acid-protein/peptide, and higher-order multi-payload LNP systems.
Move beyond single-cargo formulation logic with co-encapsulation strategies that connect payload compatibility, lipid composition, loading efficiency, particle quality, and functional sample requirements.
BOC Sciences supports multi-payload LNP systems classified by payload capacity and production scale. Instead of using restricted or proprietary LNP names, our service framework focuses on formulation-relevant attributes such as payload number, payload compatibility, particle size target, loading balance, process reproducibility, and intended research use. This classification helps researchers select a practical co-encapsulation strategy for dual-payload, triple-payload, and higher-order LNP development while maintaining clear analytical expectations.
| LNP System Category | Description | Request Information |
|---|---|---|
| Dual-Payload LNPs | Designed for co-encapsulation of up to two payloads, with a typical particle size range of 65-165 nm depending on lipid composition, payload type, and process conditions. This category is suitable for nucleic acid-nucleic acid, nucleic acid-small molecule, nucleic acid-protein/peptide, and hydrophilic-hydrophobic dual-payload systems. Development focuses on balanced loading, reduced free payload interference, particle-size control, and confirmation that both cargos remain detectable after purification and buffer exchange. | Inquiry |
| Targeted Dual-Payload LNPs | Designed for up to two encapsulated payloads combined with a surface functional component, with a typical particle size range of 65-165 nm. These systems are suitable when researchers need dual-cargo delivery together with surface-displayed ligands, antibody fragments, peptides, or other cell-interaction motifs. Formulation development emphasizes surface density control, particle stability, reduced aggregation, and differentiation between encapsulated payloads and surface-associated components. | Inquiry |
| Triple-Payload LNPs | Designed for co-encapsulation of up to three payloads, commonly targeting a particle size range of 65-125 nm when payload compatibility and formulation conditions allow. This category is suitable for systems such as dual RNA-small molecule, RNA-protein-peptide, RNA-peptide-small molecule, or other multi-mechanism research formulations. Development requires payload ratio matrix screening, compatibility assessment, and orthogonal analytical methods to reduce selective cargo loss and confirm final payload composition. | Inquiry |
| High-Capacity Multi-Payload LNPs | Designed for co-encapsulation of up to four payloads, with a typical particle size range of 65-125 nm depending on total payload burden and formulation feasibility. These systems support complex co-delivery studies involving multiple nucleic acids, nucleic acid-protein combinations, nucleic acid-small molecule combinations, or higher-order payload systems. Development focuses on cargo-cargo interference, particle heterogeneity, selective leakage, payload ratio drift, and payload-specific quantification after LNP disruption. | Inquiry |
| Compartmentalized Multi-Payload LNPs | Designed for co-encapsulation of two to four payloads that benefit from different localization environments within or on the LNP, commonly within a 65-125 nm particle size range. These may include aqueous-core-associated nucleic acids, lipid-matrix-associated small molecules, surface-associated peptides, or interface-localized functional components. The formulation strategy aims to reduce payload displacement, improve retention, and maintain payload balance under dilution or assay-relevant conditions. | Inquiry |
| Feasibility Screening Scale Multi-Payload LNPs | Used for early co-encapsulation assessment of two to four payloads before larger formulation development. This scale is suitable for evaluating whether selected payloads can be co-loaded into one LNP system without obvious precipitation, severe aggregation, broad PDI, or major selective payload loss. We screen payload compatibility, input ratio, lipid composition, particle size, PDI, zeta potential, and free payload fraction to identify practical formulation directions. | Inquiry |
| Optimization Scale Multi-Payload LNPs | Designed for systematic multi-condition formulation comparison after initial co-encapsulation feasibility is confirmed. This scale supports two- to four-payload systems and focuses on payload ratio matrices, total payload-to-lipid ratios, ionizable lipid levels, PEG-lipid content, flow parameters, purification methods, and buffer conditions. The goal is to improve loading balance, particle uniformity, payload retention, and batch-to-batch reproducibility. | Inquiry |
| Analytical Characterization Scale Multi-Payload LNPs | Supports preparation of co-loaded LNP samples for detailed particle attribute analysis, payload-specific loading analysis, free payload differentiation, retention evaluation, and in vitro assay preparation. This category is useful when researchers need sufficient material to compare candidate formulations using particle size, PDI, zeta potential, payload recovery, recovered payload ratio, and leakage behavior under assay-relevant conditions. | Inquiry |
| Research Sample Preparation Scale Multi-Payload LNPs | Used when a formulation candidate has been selected and researchers need characterized co-loaded LNP samples for downstream biological evaluation. This service category supports reproducible preparation of two- to four-payload LNPs, with attention to payload ratio preservation, particle-size consistency, buffer compatibility, reduced free payload interference, and clear reporting of formulation attributes for research-use interpretation. | Inquiry |
Multi-payload LNP projects often fail when payload loading, particle formation, purification, and analytical confirmation are treated separately. We address them as interconnected formulation variables.
✔ Unbalanced Payload Loading
One cargo may dominate encapsulation while another remains free or poorly associated. We screen payload input ratios, lipid-to-total-payload ratio, ionizable lipid content, and mixing sequence to improve final co-loading balance.
✔ Cargo-Cargo Precipitation or Aggregation
Proteins, peptides, nucleic acids, and small molecules may interact unfavorably before or during LNP assembly. We evaluate buffer composition, pH, ionic strength, component order, and concentration to reduce precipitation and aggregation risk.
✔ Broad PDI and Particle Heterogeneity
Multi-payload association can change nucleation and growth behavior during LNP formation. We optimize flow rate ratio, total flow rate, lipid concentration, and aqueous-to-organic phase conditions through microfluidic LNP production services when controlled mixing is needed.
✔ Selective Payload Loss During Purification
One payload may be retained while another is removed during dialysis, filtration, or buffer exchange. We compare purification routes and use free payload removal for LNP encapsulation strategies to reduce unencapsulated cargo while protecting the intended co-loaded fraction.
✔ Difficulty Measuring Each Payload
Co-loaded systems require analytical methods that can distinguish one payload from another and separate encapsulated cargo from free or surface-associated cargo. We combine disruption-based analysis, orthogonal assays, and nanoparticle drug loading analysis approaches to improve data confidence.
✔ Payload Ratio Drift After Dilution or Storage
Co-loaded LNPs may show acceptable initial loading but lose one payload faster than another after dilution, storage, or incubation in assay media. We evaluate lipid matrix composition, PEG-lipid level, buffer conditions, and retention behavior to improve formulation robustness.
BOC Sciences provides practical experience in co-encapsulation feasibility, multi-ratio formulation screening, free payload differentiation, loading analysis, particle characterization, and activity-aware formulation optimization.
We review each payload's molecular weight, charge, solubility, buffer composition, structural sensitivity, target ratio, analytical detectability, and intended in vitro use to define a practical co-encapsulation strategy.
Lipid molar ratios, total payload concentration, individual payload ratio, pH, ionic strength, mixing sequence, and flow parameters are screened to identify promising co-loading windows.
Candidate co-loaded LNPs are prepared under controlled conditions, followed by residual solvent reduction, free payload removal, and exchange into a buffer compatible with both particle stability and payload integrity.
We report particle size, PDI, zeta potential, payload-specific loading, free payload assessment, recovered payload ratio, retention behavior, and key formulation observations to support the next research decision.
Challenge: A biotechnology research team needed a co-encapsulated LNP containing one mRNA payload and one siRNA payload for a pathway modulation study. Their initial formulation produced particles around 130-190 nm with PDI frequently above 0.28. Total RNA encapsulation appeared acceptable, but post-disruption analysis showed that the recovered mRNA-to-siRNA ratio shifted from the intended 1:2 input ratio to approximately 1:0.6, resulting in inconsistent expression and knockdown readouts in in vitro cell models.
Diagnosis: The original formulation used a single total RNA-to-lipid ratio optimized for mRNA alone. The shorter siRNA payload competed differently with the ionizable lipid system and was more likely to remain in the free fraction after particle formation. Increasing total RNA input improved siRNA signal slightly but broadened particle size distribution, indicating that simple payload excess was not solving the co-loading problem.
Solution: BOC Sciences designed a matrix screen covering three mRNA-to-siRNA input ratios, four total RNA-to-lipid ratios, two ionizable lipid levels, and three microfluidic flow conditions. We compared simultaneous mixing with a stepwise RNA pre-mixing approach and evaluated each candidate by DLS, zeta potential, total RNA recovery, payload-specific fluorescence analysis, and free RNA assessment after purification. Conditions with PDI above 0.25 or strong free siRNA signal were excluded before functional sample preparation.
Result: The selected formulation produced co-loaded LNPs with an average size of 85-115 nm and PDI below 0.20 across three preparation runs. The recovered mRNA-to-siRNA ratio was maintained near the intended range, with both payloads showing above 70% encapsulation based on payload-specific analysis. The client obtained a more interpretable LNP sample set for comparing expression, knockdown, and combined pathway response.
Challenge: A research group working with an RNA-peptide co-delivery system observed immediate turbidity during mixing and unstable particles after buffer exchange. The peptide was a 22-amino-acid cationic sequence intended for intracellular functional evaluation together with a short RNA payload. Initial LNP batches showed particle size above 220 nm, PDI above 0.35, and a large surface-associated peptide fraction that interfered with cell uptake interpretation.
Diagnosis: The peptide carried multiple positive charges and showed partial self-association at the formulation pH. When mixed directly with RNA before LNP assembly, it formed heterogeneous complexes that disrupted nanoparticle nucleation. The original PEG-lipid level was also too low to control peptide-driven surface association, causing particle bridging and size drift after purification.
Solution: Our team evaluated peptide input concentration, RNA-to-peptide ratio, aqueous phase pH, PEG-lipid percentage, and two mixing sequences. Instead of direct RNA-peptide premixing at high concentration, we used a diluted sequential assembly approach that reduced local charge neutralization. A moderate PEG-lipid increase improved colloidal stability, while lipid-to-total-payload ratio screening helped reduce external peptide adsorption. Candidate LNPs were analyzed for particle size, PDI, zeta potential, RNA loading, peptide association, free peptide content, and retention after dilution into assay medium.
Result: The optimized condition generated RNA-peptide co-loaded LNPs with particle size around 95-125 nm and PDI below 0.22 after buffer exchange. Free peptide signal decreased by more than 55% compared with the starting formulation, and the RNA loading remained above 65%. The client received a cleaner, more stable co-delivery sample suitable for comparative cellular uptake and intracellular response studies.
Rich Co-Encapsulation ExperienceMulti-payload formulation experience covers nucleic acid-nucleic acid, nucleic acid-small molecule, nucleic acid-protein/peptide, and triple-payload LNP systems.
Precise Payload Ratio ControlInput ratio, lipid-to-payload ratio, mixing order, and purification conditions are optimized to reduce selective loss and maintain payload balance.
Systematic Compatibility EvaluationpH, buffer, charge interaction, solubility, aggregation risk, and addition sequence are assessed before co-loading to improve formulation feasibility.
Payload-Specific Analytical CapabilityEach payload, free fraction, encapsulated fraction, and surface-associated component can be differentiated to confirm true co-encapsulation performance.
Data-Driven Co-Delivery GuidanceParticle size, PDI, zeta potential, payload loading, ratio drift, and retention data are connected to guide the next formulation decision.
LNP co-encapsulation is suitable for research programs that require two or more functional payloads to be delivered within the same lipid nanoparticle system. Common combinations may include mRNA with siRNA, mRNA with a protein antigen, nucleic acids with small-molecule modulators, CRISPR-related RNA with protein components, or a therapeutic payload with a fluorescent tracer for uptake and localization studies. The key consideration is not only whether each payload can be loaded, but whether the formulation can maintain the intended payload ratio, particle uniformity, colloidal stability, and functional relevance. BOC Sciences designs co-encapsulation strategies according to payload size, charge, hydrophilicity, structural sensitivity, and analytical feasibility, helping researchers build more interpretable multi-payload LNP systems.
LNP co-encapsulation is technically challenging because different payloads often require different loading mechanisms. Nucleic acids may rely strongly on electrostatic interaction with ionizable or cationic lipids, while proteins can be sensitive to pH shift, organic solvent exposure, interfacial stress, aggregation, and surface adsorption. Hydrophobic small molecules may preferentially partition into lipid regions rather than the aqueous core. When these payloads are formulated together, one component may load efficiently while another remains free, leaks after dilution, or destabilizes the particle. A successful LNP co-encapsulation project therefore requires coordinated optimization of lipid composition, payload input ratio, buffer conditions, mixing parameters, purification method, and multi-payload analytical confirmation.
Payload ratio optimization in LNP begins with the biological objective of the study and then translates that objective into a practical formulation design. Researchers need to define whether the payloads should act synergistically, provide sequential functions, enable tracking, or support comparative delivery analysis. From there, input ratios, lipid-to-payload ratio, aqueous phase pH, ionic strength, total lipid concentration, flow rate ratio, and post-formulation purification conditions can be screened. The optimal ratio is not necessarily the highest loading condition; it is the condition that provides a useful balance among encapsulation efficiency, particle size, PDI, zeta potential, payload retention, and functional readout. BOC Sciences can support matrix-based formulation screening to identify multi-payload LNP candidates with balanced composition and reliable particle attributes.
Yes, LNP co-encapsulation can affect payload activity, especially when one or more payloads are structurally sensitive. Proteins, enzymes, antibody fragments, cytokines, growth factors, RNP complexes, and conformationally dependent antigens may lose activity or binding performance if exposed to unfavorable pH, solvent interfaces, local charge imbalance, concentration stress, or incompatible purification conditions. In multi-payload systems, additional interactions between payloads can also influence stability or function. For this reason, co-encapsulated LNP development should include activity-aware formulation design, mild buffer selection, controlled lipid charge density, suitable PEG-lipid levels, and functional readouts when applicable. Analytical evaluation should assess each payload individually rather than relying only on total encapsulation or particle size.
True LNP co-encapsulation requires evidence that multiple payloads are associated with the nanoparticle population in a meaningful and reproducible way, rather than simply being present together in the same sample. Confirmation may involve measuring total and free payload levels before and after purification, analyzing each payload after particle disruption, comparing single-payload and multi-payload formulations, and evaluating whether the payloads co-migrate with the LNP fraction during separation. Depending on the payload types, suitable methods may include fluorescence analysis, chromatographic assays, gel-based analysis, protein quantification, nucleic acid quantification, particle characterization, and functional readouts. BOC Sciences integrates payload-specific analysis with particle size, PDI, zeta potential, and retention testing to help researchers interpret whether co-encapsulation has been achieved reliably.
